**BREXAFEMME® (ibrexafungerp tablets)**

**Frequently Asked Questions**

**What is BREXAFEMME?**

BREXAFEMME is a prescription medicine used to treat vulvovaginal candidiasis (VVC), also known as vaginal yeast infection. It is a triterpenoid antifungal with fungicidal activity, which means it kills the fungal cell.[[1]](#endnote-1)

**What is a vaginal yeast infection?**

A vaginal yeast infection is a fungal infection that may cause irritation, discharge, itching, and burning of the vagina and vulva (the tissue at the vaginal opening). Vaginal yeast infections are common; an estimated 70-75% of women worldwide will have at least one episode in their lifetimes, and many women experience several episodes.[[2]](#endnote-2)

**How is BREXAFEMME taken?**

BREXAFEMME tablets are taken by mouth, with or without food. The recommended dosage is two tablets by mouth in the morning and two tablets in the evening about 12 hours apart. If prescribed BREXAFEMME, patients should follow healthcare provider instructions.

**How is BREXAFEMME different than other approved treatments?**

BREXAFEMME, the first and only oral non-azole treatment option approved for vaginal yeast infection, targets the yeast causing the infection differently than other medications. It belongs to new and different class of medication known as the triterpenoid antifungals. It works by inhibiting glucan synthase, an enzyme in fungal cells, but not human cells. Inhibition of glucan synthase disrupts the fungal cell wall integrity, killing the fungal cells.1,[[3]](#endnote-3)

**What are the possible side effects of BREXAFEMME?**

The most common side effects include diarrhea, nausea, abdominal pain, dizziness, and vomiting. For more detail information, please see the full prescribing and patient information [here](https://d1io3yog0oux5.cloudfront.net/scynexis/files/pages/scynexis/db/pis/Digital+Ibrexafungerp+Prescribing+Information+%28PI%29.pdf#page=5).

**Is there a co-pay program for patients who need assistance with paying for BREXAFEMME?**

As part of its commitment to ensuring patient access, SCYNEXIS has implemented programs to remove potential barriers and help patients receive treatment. A co-pay assistance savings program is available for eligible commercially insured patients. More information can be found [here](https://www.brexafemme.com/).

**IMPORTANT SAFETY INFORMATION**

* BREXAFEMME is contraindicated during pregnancy and in patients with a history of hypersensitivity to ibrexafungerp
* BREXAFEMME administration during pregnancy may cause fetal harm based on animal studies. Prior to initiating treatment, verify pregnancy status in females of reproductive potential and advise them to use effective contraception during treatment
* When administering BREXAFEMME with strong CYP3A inhibitors, the dose of BREXAFEMME should be reduced to 150 mg twice a day for one day. Administration of BREXAFEMME with strong CYP3A inducers should be avoided
* Most common adverse reactions observed in clinical trials (incidence ≥2%) were diarrhea, nausea, abdominal pain, dizziness, and vomiting

To report SUSPECTED ADVERSE REACTIONS, contact SCYNEXIS, Inc. at 1-888-982-SCYX (1-888-982-7299) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](https://www.globenewswire.com/Tracker?data=8Q-vsFco37CsDuK6olGCvDqf_ny2WCgO7hulDP2VMxkf5Ct8M4oKgvNAqdQ2tJgqfd6sMoxRoe6g8917RgHo3QyUbNyxBKsghNOIOdvu_VE=).

For more information, visit [www.brexafemme.com](http://www.brexafemme.com). Please click [here](https://www.globenewswire.com/Tracker?data=An-ya9HX9ayjPzM7hAbcAVe7v8ggDNVxidVTLN0V0UESZVoG2oLB8EgW13JSJS9HpyFwtdDRV0H84Zbkxv-THPtSz8GdDejnmEDCFSGub1wjFO7YjCWeKfGwYetC_ib2) for full Prescribing Information.

1. BREXAFEMME® U.S. [prescribing information](https://d1io3yog0oux5.cloudfront.net/scynexis/files/pages/scynexis/db/pis/Digital+Ibrexafungerp+Prescribing+Information+%28PI%29.pdf#page=5). June 2021. [↑](#endnote-ref-1)
2. 2 Centers for Disease Control and Prevention. Sexually transmitted infections treatment guidelines, 2021. Published July 22, 2021. Accessed September 16, 2021 https://www.cdc.gov/std/treatment-guidelines/candidiasis.htm [↑](#endnote-ref-2)
3. Nosanchuk JD. Current status and future of antifungal therapy for systemic mycoses. Recent Pat *Antiinfect Drug Discov*. 2006 Jan;1(1):75-84. doi: 10.2174/157489106775244109. PMID: 18221136. <https://pubmed.ncbi.nlm.nih.gov/18221136/> Accessed September 7, 2021. [↑](#endnote-ref-3)